Clinical Trials Browser

Phase NA × Cholangiocarcinoma × Immunotherapy, Active × Clear all

NCT05247996 2022-02-21

TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma

Phase NA Unknown

Gastrointestinal

Cholangiocarcinoma